IRAK-1(Phospho Thr387) Polyclonal Antibody

This gene encodes the interleukin-1 receptor-associated kinase 1, one of two putative serine/threonine kinases that become associated with the interleukin-1 receptor (IL1R) upon stimulation. This gene is partially responsible for IL1-induced upregulation of the transcription factor NF-kappa B. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

The IRAK-1(Phospho Thr387) Polyclonal Antibody is a highly specific and sensitive tool designed for the detection and quantification of IRAK-1 protein phosphorylated at threonine 387. This antibody is produced using advanced techniques and rigorous quality control measures to ensure optimal performance and reliability.

The IRAK-1 protein plays a crucial role in the innate immune response by mediating the signaling cascade downstream of Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs). Phosphorylation of IRAK-1 at threonine 387 is a key event in the activation of this protein and subsequent initiation of downstream signaling pathways.

This polyclonal antibody has been extensively validated for its specificity and sensitivity in various experimental settings, including Western blotting, immunoprecipitation, and immunofluorescence. It exhibits minimal cross-reactivity with non-phosphorylated IRAK-1 and other related proteins, ensuring accurate and reliable results.

The IRAK-1(Phospho Thr387) Polyclonal Antibody is supplied as a liquid formulation in a convenient size, allowing for easy handling and storage. It is recommended for use in a wide range of research applications, including but not limited to the study of innate immune signaling, inflammation, and host-pathogen interactions.

With its high specificity, sensitivity, and reliability, the IRAK-1(Phospho Thr387) Polyclonal Antibody is an indispensable tool for researchers in the field of immunology and molecular biology. It offers a valuable means to investigate the intricate mechanisms underlying innate immune responses and holds great potential for the development of novel therapeutic strategies targeting IRAK-1 signaling pathways.